《新股》泰德醫藥(03880.HK)今起招股入場費3,091元 引石藥(01093.HK)爲基投
合約研究,開發及生產機構(CRDMO)泰德醫藥(03880.HK)公佈在港招股詳情,計劃全球發售1,680萬股H股,香港公開發售佔10%(約168萬股),國際配售部分佔90%(1,512萬股),發售價每股28.4至30.6元,最高集資約5.14億元,每手買賣單位100股,入場費爲約3,090.85元。招股期由今日(20日)起至下週三(25日)止,預計6月30日掛牌,由摩根士丹利及中信證券擔任聯席保薦人。
泰德醫藥今次招股將引入石藥(01093.HK)及騰訊(00700.HK)前高管吳宵光創立的微光創投爲基石投資者,分別認購500萬美元等值股份。
按發售中位價每股29.5元計,是次招股集資淨額爲約4.11億元,其中約76.4%主要用於在美國及中國建設設施,約4.1%會用於提升在中國的產能,約9.5%用於拓展歐洲銷售網絡,餘下10%用作營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.